Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Trial Details

NCT ID
NCT06984146
Phase
PHASE2
Sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Nivolumab
  • Doxorubicin
  • Vinblastine
  • Dacarbazine
Locations (sample)
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
  • No past history of autoimmune disease
  • Age \> 18 years
  • Ejection fraction \> 50%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →